Clinical studies recruiting near Overland Park

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · University of Kansas Cancer Center-Overland Park · National Cancer Institute (NCI) · NCT05564390 Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small C
Phase 3 · University of Kansas Cancer Center-Overland Park · NRG Oncology · NCT05624996 Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated C
Phase 3 · University of Kansas Cancer Center-Overland Park · Alliance for Clinical Trials in Oncology · NCT07321652 Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally A
Phase 1/Phase 2 · University of Kansas Cancer Center-Overland Park · National Cancer Institute (NCI) · NCT04172532 Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM
Phase 2 · University of Kansas Cancer Center-Overland Park · SWOG Cancer Research Network · NCT06769126 Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Phase 3 · University of Kansas Cancer Center-Overland Park · NRG Oncology · NCT05946213 Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastati
Phase 3 · University of Kansas Cancer Center-Overland Park · Alliance for Clinical Trials in Oncology · NCT06931340 Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-
Phase 3 · University of Kansas Cancer Center-Overland Park · NRG Oncology · NCT06500481 ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · University of Kansas Cancer Center-Overland Park · Alliance for Clinical Trials in Oncology · NCT06876714 Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry
Phase N/A · KCCC Overland Park · University of Kansas Medical Center · NCT02302742 Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · University of Kansas Cancer Center-Overland Park · National Cancer Institute (NCI) · NCT04269902 Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NI
Phase 1 · University of Kansas Cancer Center-Overland Park · National Cancer Institute (NCI) · NCT03816345 Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely
Phase 3 · University of Kansas Cancer Center-Overland Park · NRG Oncology · NCT03180268 HER2-positive Breast Cancer Registry
Phase N/A · KUCC - Indian Creek · Priyanka Sharma · NCT06603597 SELUTION 4 De Novo Small Vessel IDE Trial
NA · HCA Overland Park · M.A. Med Alliance S.A. · NCT05946629 Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Phase 2 · University of Kansas Cancer Center-Overland Park · SWOG Cancer Research Network · NCT05633615 A 26-Wk Study to Assess Safety & Efficacy of Tenapanor for T/t of Chronic Idiopathic Constipation in Adults
Phase 3 · DelRicht Clinical Research - Overland Park · Ardelyx · NCT07382167 De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Eq
Phase 3 · University of Kansas Cancer Center-Overland Park · NRG Oncology · NCT04852887 Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide,
Phase 3 · University of Kansas Cancer Center-Overland Park · National Cancer Institute (NCI) · NCT06058377 Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherap
Phase 2 · The University of Kansas Cancer Center, Overland Park Clinic · University of Kansas Medical Center · NCT04992780 Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Remo
Phase 2/Phase 3 · University of Kansas Cancer Center-Overland Park · National Cancer Institute (NCI) · NCT05987241 Trial of Neoadjuvant THP vs TCHP for HER2-Amplified/Positive Breast Cancer
Phase 2 · KUCC - Indian Creek · University of Kansas Medical Center · NCT07220135 Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Phase 3 · University of Kansas Cancer Center Overland Park · GOG Foundation · NCT05659381 Vascular Closure With a Device Compared to Manual Compression After Atrial Fibrillation Ablation: The LockeT II Study
NA · Kansas City Heart Rhythm Institute - Roe Clinic · Kansas City Heart Rhythm Research Foundation · NCT06078735 Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had
Phase 2/Phase 3 · University of Kansas Cancer Center-Overland Park · SWOG Cancer Research Network · NCT06616584 S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac
Phase 3 · Menorah Medical Center · SWOG Cancer Research Network · NCT03418961 Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors
Phase N/A · University of Kansas Cancer Center-Overland Park · ECOG-ACRIN Cancer Research Group · NCT06002828 Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
NA · University of Kansas Cancer Center-Overland Park · Alliance for Clinical Trials in Oncology · NCT07283939 Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
Phase 1 · University of Kansas Cancer Center-Overland Park · National Cancer Institute (NCI) · NCT04633239 Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer
Phase 2 · University of Kansas Cancer Center-Overland Park · National Cancer Institute (NCI) · NCT07195734

Look up another city

Look up another condition